219 related articles for article (PubMed ID: 32503874)
1. Efficacy of remdesivir in patients with COVID-19: a protocol for systematic review and meta-analysis of randomised controlled trials.
Gebrie D; Getnet D; Manyazewal T
BMJ Open; 2020 Jun; 10(6):e039159. PubMed ID: 32503874
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial.
Wang Y; Zhou F; Zhang D; Zhao J; Du R; Hu Y; Cheng Z; Gao L; Jin Y; Luo G; Fu S; Lu Q; Du G; Wang K; Lu Y; Fan G; Zhang Y; Liu Y; Ruan S; Liu W; Jaki T; Hayden FG; Horby PW; Cao B; Wang C
Trials; 2020 May; 21(1):422. PubMed ID: 32448345
[TBL] [Abstract][Full Text] [Related]
3. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.
Spinner CD; Gottlieb RL; Criner GJ; Arribas López JR; Cattelan AM; Soriano Viladomiu A; Ogbuagu O; Malhotra P; Mullane KM; Castagna A; Chai LYA; Roestenberg M; Tsang OTY; Bernasconi E; Le Turnier P; Chang SC; SenGupta D; Hyland RH; Osinusi AO; Cao H; Blair C; Wang H; Gaggar A; Brainard DM; McPhail MJ; Bhagani S; Ahn MY; Sanyal AJ; Huhn G; Marty FM;
JAMA; 2020 Sep; 324(11):1048-1057. PubMed ID: 32821939
[TBL] [Abstract][Full Text] [Related]
4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
5. Remdesivir for the Treatment of COVID-19: A Systematic Review of the Literature.
Musa A; Pendi K; Hashemi A; Warbasse E; Kouyoumjian S; Yousif J; Blodget E; Stevens S; Aly B; Baron DA
West J Emerg Med; 2020 May; 21(4):737-741. PubMed ID: 32726230
[TBL] [Abstract][Full Text] [Related]
6. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Wang Y; Zhang D; Du G; Du R; Zhao J; Jin Y; Fu S; Gao L; Cheng Z; Lu Q; Hu Y; Luo G; Wang K; Lu Y; Li H; Wang S; Ruan S; Yang C; Mei C; Wang Y; Ding D; Wu F; Tang X; Ye X; Ye Y; Liu B; Yang J; Yin W; Wang A; Fan G; Zhou F; Liu Z; Gu X; Xu J; Shang L; Zhang Y; Cao L; Guo T; Wan Y; Qin H; Jiang Y; Jaki T; Hayden FG; Horby PW; Cao B; Wang C
Lancet; 2020 May; 395(10236):1569-1578. PubMed ID: 32423584
[TBL] [Abstract][Full Text] [Related]
7. Remdesivir for the Treatment of Covid-19 - Final Report.
Beigel JH; Tomashek KM; Dodd LE; Mehta AK; Zingman BS; Kalil AC; Hohmann E; Chu HY; Luetkemeyer A; Kline S; Lopez de Castilla D; Finberg RW; Dierberg K; Tapson V; Hsieh L; Patterson TF; Paredes R; Sweeney DA; Short WR; Touloumi G; Lye DC; Ohmagari N; Oh MD; Ruiz-Palacios GM; Benfield T; Fätkenheuer G; Kortepeter MG; Atmar RL; Creech CB; Lundgren J; Babiker AG; Pett S; Neaton JD; Burgess TH; Bonnett T; Green M; Makowski M; Osinusi A; Nayak S; Lane HC;
N Engl J Med; 2020 Nov; 383(19):1813-1826. PubMed ID: 32445440
[TBL] [Abstract][Full Text] [Related]
8. BET 1: The role of remdesivir in COVID-19 infection.
Baombe JP
Emerg Med J; 2020 Aug; 37(8):522-523. PubMed ID: 32753375
[TBL] [Abstract][Full Text] [Related]
9. Liver injury in remdesivir-treated COVID-19 patients.
Zampino R; Mele F; Florio LL; Bertolino L; Andini R; Galdo M; De Rosa R; Corcione A; Durante-Mangoni E
Hepatol Int; 2020 Sep; 14(5):881-883. PubMed ID: 32725454
[No Abstract] [Full Text] [Related]
10. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
11. Antiviral treatment for COVID-19: the evidence supporting remdesivir.
Richardson C; Bhagani S; Pollara G
Clin Med (Lond); 2020 Nov; 20(6):e215-e217. PubMed ID: 32863273
[TBL] [Abstract][Full Text] [Related]
12. Favipiravir for treating patients with novel coronavirus (COVID-19): protocol for a systematic review and meta-analysis of randomised clinical trials.
Arab-Zozani M; Hassanipour S; Ghoddoosi-Nejad D
BMJ Open; 2020 Jul; 10(7):e039730. PubMed ID: 32737100
[TBL] [Abstract][Full Text] [Related]
13. Audio Interview: New Data on Remdesivir in Covid-19.
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2020 May; 382(22):e94. PubMed ID: 32459948
[No Abstract] [Full Text] [Related]
14. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
15. Remdesivir against COVID-19 and Other Viral Diseases.
Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
[TBL] [Abstract][Full Text] [Related]
16. Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status.
Antinori S; Cossu MV; Ridolfo AL; Rech R; Bonazzetti C; Pagani G; Gubertini G; Coen M; Magni C; Castelli A; Borghi B; Colombo R; Giorgi R; Angeli E; Mileto D; Milazzo L; Vimercati S; Pellicciotta M; Corbellino M; Torre A; Rusconi S; Oreni L; Gismondo MR; Giacomelli A; Meroni L; Rizzardini G; Galli M
Pharmacol Res; 2020 Aug; 158():104899. PubMed ID: 32407959
[TBL] [Abstract][Full Text] [Related]
17. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.
Goldman JD; Lye DCB; Hui DS; Marks KM; Bruno R; Montejano R; Spinner CD; Galli M; Ahn MY; Nahass RG; Chen YS; SenGupta D; Hyland RH; Osinusi AO; Cao H; Blair C; Wei X; Gaggar A; Brainard DM; Towner WJ; Muñoz J; Mullane KM; Marty FM; Tashima KT; Diaz G; Subramanian A;
N Engl J Med; 2020 Nov; 383(19):1827-1837. PubMed ID: 32459919
[TBL] [Abstract][Full Text] [Related]
18. Data Monitoring for the Chinese Clinical Trials of Remdesivir in Treating Patients with COVID-19 During the Pandemic Crisis.
Shih WJ; Yao C; Xie T
Ther Innov Regul Sci; 2020 Sep; 54(5):1236-1255. PubMed ID: 32865809
[TBL] [Abstract][Full Text] [Related]
19. Remdesivir for the treatment of COVID-19.
Ansems K; Grundeis F; Dahms K; Mikolajewska A; Thieme V; Piechotta V; Metzendorf MI; Stegemann M; Benstoem C; Fichtner F
Cochrane Database Syst Rev; 2021 Aug; 8(8):CD014962. PubMed ID: 34350582
[TBL] [Abstract][Full Text] [Related]
20. Impact of non-pharmaceutical interventions for reducing transmission of COVID-19: a systematic review and meta-analysis protocol.
Regmi K; Lwin CM
BMJ Open; 2020 Oct; 10(10):e041383. PubMed ID: 33093038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
